The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor pathway inhibitor.

High malpractice costs, restrictive legislation, and rising burnout are driving Ob/Gyns out. What can be done?

Subcutaneous pembrolizumab reduces time demands for both the patient and clinician, all while providing a consistent efficacy ...

Deficiency of the pancreatic progenitor cell differentiation and proliferation factor gene was identified as a risk factor ...

Patients with MASLD had nearly twice the all-cause mortality rate as the general population, suggesting the need for ...

Advances in PCI over the past decade mean the procedure can now approximate results only previously achieved with open-heart bypass surgery, new data show.

Just as effective as the high dose, low-dose apixaban prevents long-term recurrent venous thromboembolism in patients with ...

A show of hands at the ACC town hall demonstrated unity as specialists investigate options for a new certifying board outside the current one or with two parent sponsors.

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...

A comprehensive literature review was conducted for all medications on the formulary of Bedlam Clinic, a free evening clinic for the medically indigent or working poor, offered by the University ...

The addition of the aldosterone synthase inhibitor helped lower blood pressure in patients with resistant hypertension.